

**Table S1** Lung cancer morphology codes

Type of lung cancer	Morphology codes
Non-small cell lung cancer	
Adenocarcinoma	80503, 80523, 81303, 81403, 81406, 82503, 82513, 82523, 82533, 82543, 82553, 82563, 82573, 82603, 82653, 84803, 84813, 85503, 85513, 85713, 85723, 85743, 85753, 85763
Squamous cell carcinoma	80703, 80713, 80723, 80733, 80743, 80763, 80833, 80843
Large cell carcinoma	80033, 80043, 80123, 80133, 80143, 80303, 80313, 80323, 80343, 80353, 82463
Adenosquamous	85603, 85623
Not otherwise specified	80103, 80203, 80463, 81233
Small cell lung cancer	80023, 80413, 80423, 80443, 80453
Unspecified	80003, 80013, 82303

Reprinted from Butler SJ, Louie AV, Sutradhar R, *et al.* Palliative Care Among Lung Cancer Patients With and Without COPD: A Population-Based Cohort Study. *J Pain Symptom Manage* 2023;66:611-620.e4. Copyright 2023, with permission from Elsevier.

**Table S2** Characteristics of individuals who completed the ESAS within 90 days of diagnosis and individuals who did not complete the ESAS within 90 days of diagnosis (n=82,576)

Characteristics	Did not complete ESAS within 90-days of diagnosis (n=43,478)	Completed ESAS within 90-days of diagnosis (n=38,898)	SMD
COPD status, n (%)			
Previously diagnosed COPD	20,333 (46.8)	16,697 (42.9)	0.077
Newly diagnosed COPD	4,447 (10.2)	3,930 (10.1)	0.004
No COPD	18,698 (43.0)	18,271 (47.0)	0.08
Stage, n (%)			
Early (I/II)	14,259 (32.8)	8,903 (22.9)	0.222
Advanced (III/IV)	29,219 (67.2)	29,995 (77.1)	
Type of lung cancer, n (%)			
NSCLC	32,381 (74.5)	31,868 (81.9)	0.182
SCLC	4,146 (9.5)	5,315 (13.7)	0.128
Unspecified	6,951 (16.0)	1,715 (4.4)	0.39
Age, mean (SD)	71.6 (10.5)	68.9 (10.2)	0.261
Sex, n (%)			
Male	22,569 (51.9)	19,876 (51.1)	0.016
Female	20,909 (48.1)	19,022 (48.9)	
Rurality & income quintile, n (%)			
Rural	6,187 (14.2)	6,343 (16.3)	0.058
1 (lowest)	9,740 (22.4)	7,408 (19.0)	0.083
2	8,491 (19.5)	7,400 (19.0)	0.013
3	7,111 (16.4)	6,386 (16.4)	0.002
4	6,296 (14.5)	5,919 (15.2)	0.021
5 (highest)	5,653 (13.0)	5,442 (14.0)	0.029
Region of Ontario, n (%)			
Central	10,638 (24.5)	7,989 (20.5)	0.094
East	12,006 (27.6)	11,949 (30.7)	0.07
North	3,291 (7.6)	4,060 (10.4)	0.101
West	13,677 (31.5)	12,945 (33.3)	0.038
Toronto	3,866 (8.9)	1,955 (5.0)	0.154
Immigration status, n (%)			
Recent immigrant ( $\leq 10$ years)	585 (1.3)	471 (1.2)	0.012
Long-term resident ( $> 10$ years)	2,146 (4.9)	1,696 (4.4)	0.028
Non-immigrant	40,747 (93.7)	36,731 (94.4)	0.031
Comorbidity by John Hopkins Aggregated Diagnostic Groups, n (%)			
High ( $\geq 10$ )	18,061 (41.5)	14,772 (38.0)	0.073
Low ( $< 10$ )	25,417 (58.5)	24,126 (62.0)	
Specific comorbidities, n (%)			
Asthma	7,387 (17.0)	5,980 (15.4)	0.044
Congestive heart failure	6,295 (14.5)	3,845 (9.9)	0.141
Diabetes	12,215 (28.1)	9,927 (25.5)	0.058
Dementia	2,689 (6.2)	977 (2.5)	0.181

ESAS, Edmonton Symptom Assessment Scale; SMD, standardized mean difference; COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SD, standard deviation.